Oxbow Advisors’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-15,431
| Closed | -$428K | – | 242 |
|
|
2024
Q1 | $428K | Buy |
15,431
+873
| +6% | +$24.2K | 0.06% | 137 |
|
|
2023
Q4 | $419K | Sell |
14,558
-136,724
| -90% | -$4.13M | 0.06% | 132 |
|
|
2023
Q3 | $5.02M | Buy |
151,282
+131,821
| +677% | +$4.66M | 0.79% | 33 |
|
|
2023
Q2 | $714K | Buy |
19,461
+617
| +3% | +$24K | 0.11% | 101 |
|
|
2023
Q1 | $769K | Sell |
18,844
-258
| -1% | -$11.1K | 0.14% | 96 |
|
|
2022
Q4 | $979K | Buy |
19,102
+4
| +0% | +$192 | 0.18% | 82 |
|
|
2022
Q3 | $836K | Sell |
19,098
-4,625
| -19% | -$225K | 0.13% | 113 |
|
|
2022
Q2 | $1.24M | Sell |
23,723
-196
| -0.8% | -$9.99K | 0.18% | 91 |
|
|
2022
Q1 | $1.24M | Sell |
23,919
-3,628
| -13% | -$188K | 0.12% | 103 |
|
|
2021
Q4 | $1.63M | Buy |
27,547
+4
| +0% | +$198 | 0.16% | 95 |
|
|
2021
Q3 | $1.19M | Buy |
27,543
+2,237
| +9% | +$99.1K | 0.12% | 125 |
|
|
2021
Q2 | $991K | Sell |
25,306
-234,691
| -90% | -$9.13M | 0.1% | 140 |
|
|
2021
Q1 | $9.42M | Sell |
259,997
-38,325
| -13% | -$1.36M | 1.15% | 27 |
|
|
2020
Q4 | $11M | Sell |
298,322
-15,945
| -5% | -$585K | 1.41% | 19 |
|
|
2020
Q3 | $10.9M | Sell |
314,267
-7,158
| -2% | -$251K | 1.39% | 17 |
|
|
2020
Q2 | $9.97M | Buy |
321,425
+192,436
| +149% | +$6.54M | 1.45% | 17 |
|
|
2020
Q1 | $3.99M | Sell |
128,989
-1,154
| -0.9% | -$39.3K | 0.67% | 49 |
|
|
2019
Q4 | $4.84M | Sell |
130,143
-4,015
| -3% | -$143K | 0.56% | 46 |
|
|
2019
Q3 | $4.57M | Buy |
134,158
+7,666
| +6% | +$279K | 0.61% | 43 |
|
|
2019
Q2 | $5.2M | Buy |
126,492
+1,614
| +1% | +$64.1K | 0.63% | 42 |
|
|
2019
Q1 | $5.03M | Sell |
124,878
-5,615
| -4% | -$225K | 0.61% | 39 |
|
|
2018
Q4 | $5.4M | Sell |
130,493
-127,426
| -49% | -$5.29M | 0.72% | 34 |
|
|
2018
Q3 | $10.8M | Sell |
257,919
-4,473
| -2% | -$172K | 1.3% | 16 |
|
|
2018
Q2 | $9.03M | Buy |
262,392
+1,778
| +0.7% | +$60.8K | 1.15% | 24 |
|
|
2018
Q1 | $8.78M | Buy |
260,614
+5,071
| +2% | +$174K | 1.79% | 14 |
|
|
2017
Q4 | $8.78M | Sell |
255,543
-2,747
| -1% | -$93.7K | 1.64% | 12 |
|
|
2017
Q3 | $8.75M | Sell |
258,290
-110,812
| -30% | -$3.56M | 1.67% | 13 |
|
|
2017
Q2 | $11.8M | Buy |
369,102
+3,704
| +1% | +$117K | 2.08% | 7 |
|
|
2017
Q1 | $11.9M | Sell |
365,398
-4,419
| -1% | -$139K | 1.93% | 9 |
|
|
2016
Q4 | $11.4M | Sell |
369,817
-10,830
| -3% | -$331K | 1.42% | 16 |
|
|
2016
Q3 | $12.2M | Sell |
380,647
-9,654
| -2% | -$323K | 1.68% | 13 |
|
|
2016
Q2 | $13M | Sell |
390,301
-31,104
| -7% | -$993K | 1.87% | 10 |
|
|
2016
Q1 | $11.8M | Buy |
421,405
+339,533
| +415% | +$9.7M | 1.68% | 16 |
|
|
2015
Q4 | $2.51M | Sell |
81,872
-2,039
| -2% | -$64.1K | 0.31% | 95 |
|
|
2015
Q3 | $2.5M | Buy |
83,911
+8,366
| +11% | +$268K | 0.41% | 77 |
|
|
2015
Q2 | $2.4M | Buy |
75,545
+7,665
| +11% | +$250K | 0.31% | 88 |
|
|
2015
Q1 | $2.24M | Sell |
67,880
-4,607
| -6% | -$146K | 0.33% | 78 |
|
|
2014
Q4 | $2.14M | Sell |
72,487
-843
| -1% | -$24.2K | 0.3% | 84 |
|
|
2014
Q3 | $2.06M | Sell |
73,330
-137
| -0.2% | -$3.85K | 0.29% | 84 |
|
|
2014
Q2 | $2.07M | Buy |
73,467
+295
| +0.4% | +$8.41K | 0.27% | 85 |
|
|
2014
Q1 | $2.23M | Buy |
73,172
+469
| +0.6% | +$14K | 0.33% | 75 |
|
|
2013
Q4 | $2.11M | Buy |
72,703
+2,393
| +3% | +$69.6K | 0.3% | 83 |
|
|
2013
Q3 | $1.92M | Buy |
70,310
+16,051
| +30% | +$437K | 0.31% | 80 |
|
|
2013
Q2 | $1.44M | Buy |
+54,259
| New | +$1.5M | 0.25% | 78 |
|
Other funds holding PFE
Oxbow Advisors's PFE Position: Q2 2024 in Review
Oxbow Advisors sold out of Pfizer (PFE) in Q2 2024, closing a stake of 15,431 shares — an estimated $428K sold.
Oxbow Advisors first reported a position in PFE in Q2 2013 and held it in 44 quarters. The position peaked at $13M in Q2 2016. 2,873 funds tracked by Wall St. Rank hold PFE as of Q2 2024.
- Oxbow Advisors reported no remaining Pfizer position as of Q2 2024 after selling out during the quarter.
- Oxbow Advisors sold 15,431 Pfizer shares in Q2 2024, an estimated $428K.
- Oxbow Advisors first reported a position in Pfizer in Q2 2013 and held it in 44 quarters.
- Oxbow Advisors's Pfizer position peaked at $13M in Q2 2016.
- 2,873 funds tracked by Wall St. Rank held Pfizer as of Q2 2024.
Based on Oxbow Advisors's 13F filing for Q2 2024, filed 6 Aug 2024.